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Abstract 
In a randomized, cross-over pharmacokinetic study in healthy volunteers (N=14), a single 
dose of 2 g probenecid (PRO)-boosted 600 mg tenofovir disoproxil fumarate (TDF) / 400 mg 
emtricitabine (FTC) (Treatment, T +PRO) was compared with the current On-Demand HIV Pre-
Exposure Prophylaxis (PrEP) from the IPERGAY study (a 600 mg TDF/400 mg FTC on day 1 and 
300 mg TDF/200 mg FTC on days 2 and 3) (Control, C IPERGAY). PRO increased mean single 
dose plasma AUC0-∞,SD of TFV and FTC by 61% and 68%, respectively. The TFV-diphosphate (TFV-
DP) concentrations in peripheral blood mononuclear cells (PBMC) were higher (~30%) at 24 hours in 
T +PRO but then fell significantly lower (~40%) at 72 hours compared to C IPERGAY. The 
interaction between FTC and PRO was unexpected and novel. Further study is needed to determine 
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Introduction
The prevention of human immunodeficiency virus (HIV) transmission is a worldwide 
imperative. Men who have sex with men (MSM) and transgender women (TGW) are 24 and 49 times 
more likely to acquire HIV than the general population, respectively (1). The mainstay for pre-
exposure prophylaxis (PrEP) in HIV-negative individuals is the use of a combination pill containing 
300 mg of tenofovir disoproxil fumarate (TDF) and 200 mg of emtricitabine (FTC), originally marketed 
as Truvada® (2). While many new drugs or formulations are under development for HIV PrEP, 
Truvada® is one of two agents currently FDA-approved for HIV PrEP (the other being Descovy®, or 
tenofovir alafenamide with FTC). It has currently four approved therapeutic equivalents or generics 
that may increase the accessibility and affordability of TDF/FTC for HIV PrEP worldwide. The 
availability and use of TDF/FTC for HIV PrEP therapy is linked to a significant reduction in new HIV 
infections in the US (3).
Traditionally, once daily oral dosing of 300 mg TDF/200 mg FTC demonstrated a 92% 
reduction of new HIV infections in MSM and TGW at high risk for infection when coupled with 
detectable drug levels reflecting compliance (4). The IPERGAY study, an “On-Demand” dosing 
regimen of 2 tablets of 300 mg TDF/200 mg FTC 2-24 hours prior to HIV exposure and 1 tablet of 
300 mg TDF/200 mg FTC every 24 hours after sexual activity for 2 doses resulted in an 86% 
reduction in new HIV infections in MSM and TGW (5). Thus, On-Demand dosing showed comparable 
reduction in HIV transmissions to traditional daily HIV PrEP with the benefit of significantly less drug 
dosing requirements. The promise of effective HIV prophylaxis with traditional or On-Demand HIV 
PrEP regimens is highly dependent on the population and adherence (6). 
Medication adherence is a major concern in individuals at high risk for acquiring HIV and 
crucial for effective protection from HIV acquisition (4, 6). Daily or fixed-duration dosing regimens can 
be burdensome, complex, and expensive for patients. As a result, a single oral dose of TDF/FTC for 
HIV PrEP could be more advantageous for patient adherence, particularly as an On-Demand HIV 
PrEP. 
Our evaluation of the pharmacokinetic interaction with probenecid (PRO) seeks to evaluate a 
“boosting strategy” for TDF/FTC using PRO as a booster for the single-dose TDF/FTC kinetics for 
On-Demand HIV PrEP. Historically, PRO was used to minimize renal secretion of other anti-infective 
agents via organic anion transporters (OAT1 or OAT3) inhibition (7). Inhibition of renal elimination 
with PRO increases or prolongs exposure of several anti-infectives (i.e. penicillin, cefazolin) (7). 
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mediated via OAT1 and OAT3 transporters, making TFV an attractive target for the inhibitory effect 
of PRO (8). The PRO “boosting” TDF drug-drug interaction (DDI) may provide clinical benefit, 
simplified dosing and improved adherence, and offer a cost-effective and accessible single-dose 
alternative for On-Demand HIV PrEP as per the IPERGAY regimen. These potential advantages 
could improve widespread uptake of PrEP in both resource-replete and resource-limited settings. 
Thus, we studied the pharmacokinetics of TDF and FTC in combination with PRO and compared it to 
the current 3-day TDF/FTC IPERGAY HIV PrEP regimen. A prospective, randomized, open-label, 
two-phase, active-control, pivotal, cross-over, pharmacokinetic study was conducted in healthy 
volunteers to compare the plasma, urine, and peripheral blood mononuclear cells (PBMC) 





Inclusion. Non-smoker male participants (18-55 years old) within 32% of their ideal body 
weight and determined to be healthy through pre-enrollment medical assessment (medical history, 
laboratory blood and urine tests) were enrolled. The study was limited to males to minimize inter-
subject variance due to known sex-based differences in TFV disposition (9). Eligible subjects agreed 
to refrain from taking medications and herbal/dietary supplements that may interact with TDF, FTC, 
or PRO for at least two weeks prior to the start of the study and through study completion. The 
protocol was approved, in advance, by the Indiana University School of Medicine Institutional Review 
Board (IRB). All volunteers provided written informed consent that was approved by the Indiana 
University IRB. The study was performed in accordance with ethical standards in the Declaration of 
Helsinki. The study is registered in ClinicalTrials.gov under NCT03202511.
Exclusion. Subjects were excluded if they were female or had insufficient renal function 
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hepatitis B surface antigen positive), blood donations within the past two months, or conditions that 
placed the subject at a higher risk for contracting HIV during the study period (i.e. drug abuse, history 
of sexually transmitted infections, >1 sexual partner in the past 6 months).
Study Design
A prospective, randomized, open-label, two-treatment, active-control, pivotal, cross-over, 
pharmacokinetic study was conducted in healthy volunteers to compare the plasma, urine, and 
peripheral blood mononuclear cells (PBMC) pharmacokinetics of single-dose PRO with TDF/FTC to 
the current 3-day IPERGAY HIV PrEP regimen. Participants were randomized (SAS, PROC 
RANDOM, v. 9.4) by blocks of 4 to initially receive one of two sequences of treatments: (1) the test 
(“T”) treatment (2g PRO and 600mg TDF / 400mg FTC on day 1 only) and (2) the control (“C”) 
treatment IPERGAY (600mg TDF / 400mg FTC on day 1, 300mg TDF / 200mg FTC on days 2 and 
3) (Figure 4). The wash out was a period of at least 6 weeks before participants were assigned to the 
other study treatment. All medications were purchased, stored, and dispensed by the Indiana 
University Investigational Drug Services (IDS) Pharmacy (TDF/FTC NDC#:61958-0701-01; PRO 
NDC#:00378-0156-01 / 68084-0945-25). All medications were administered by trained personnel in 
the Indiana University Clinical Research Center (CRC).
Procedures and Visits. All study procedures and visits were conducted at the CRC and 
identical for both test and control treatments with the exception of drug administration regimens. 
Participants arrived at the CRC for drug administration, blood and urine collection, and safety 
evaluation on days 1-4 of the study. The first dose of drug was administered on Day 1 at time (t) 0 h 
after an overnight fast. Subjects were served a full meal 4 hours after dosing on Day 1. All doses 
were administered with ~250 mL water. Participants stayed overnight in the CRC days 1 through 2 
(0-24 hours), followed by ~1 hour outpatient visits on days 3 (48 hour) and 4 (72 hour). On day 4, 
subjects returned their urine jugs and the final blood draw was collected before completion of the 
treatment period. 
Sample Collections. Samples collected included (1) blood (plasma, isolated PBMCs) and (2) 
urine. Blood samples were drawn (~10mL) at 0, 0.5, 1, 2, 4, 8, 12, 18, 24, 48, and 72 hours post-
dose. Plasma was harvested for TFV and FTC bioanalytical and pharmacokinetic analysis. 
Peripheral blood mononuclear cell (PBMC) samples were obtained at 0, 24, 48, and 72 hours. PBMC 
samples were used for TFV-DP & FTC-TP bioanalytical and pharmacokinetic analysis. Blood 
samples for the first 24 hours were collected through a sterile indwelling catheter and by peripheral 
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collection) and all voided urine was collected for the entire 72 hours following dosing. Voided urine 
was collected for 12-hours intervals for the first 24 hours followed by 24-hours intervals for 24-48 and 
48-72 hours. Urine from each time interval was collected in a different container. After the first 24 
hours, urine void was collected at home and subjects were instructed to return urine containers at the 
following visit. Two 10-ml urine aliquots were saved from each time interval after the total urine 
volume is recorded. All blood samples were processed immediately following collection and stored 
by the Indiana University Clinical and Translational Science Laboratory (CTSL). Plasma was 
separated by centrifugation at 1200g for 10 min. PBMCs were first isolated using ficol gradient 
utilizing lymphocyte separation medium (LSM), phosphate-buffered saline (PBS) solution, 
centrifugation at 1800g for 20 min and collection of the buffy coat layer containing the lymphocytes 
for counting and analysis (9). The PBMCs were then freshly lysed in cold 70% methanol to stabilize 
nucleotides during long term storage and then ambient during the analytical extraction process. 
Plasma, urine and PBMC samples were immediately stored at -80°C pending analysis. 
Safety Evaluation. Subjects were asked to report adverse events (AEs) to study 
investigators and CRC personnel. Participants who received at least one dose of TDF/FTC were 
included in the safety analysis. AEs were documented and reported to the Indiana University IRB. 
AEs were assessed by NCI Common Toxicity Criteria guidelines and internal safety reviews. 
Objectives and Endpoints
Primary. The primary objective was to determine if the plasma and intracellular exposure of 
TFV/TFV-DP from a single PRO-boosted TDF regimen (“T” test treatment) were comparable to the 
current 3-day ‘IPERGAY’ unboosted TDF dosing regimen (“C” control treatment). The primary 
endpoints were pre-specified as the geometric mean ratio (GMR) of plasma (AUC0-72h,plasma) and 
PBMC (AUC0-72h,PBMC) exposure in the T versus C treatment arms. 
Secondary. The secondary outcome was to compare the short-term safety and tolerability of 
the T versus C treatments. 
Quantification of drugs and active metabolites. 
Plasma. TFV and FTC were simultaneously quantified from plasma samples utilizing a 
validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay previously published 
for TFV and FTC (10). Briefly, analytes chromatographic separation were done using a Synergi 
Polar-RP column (100 × 2.0 mm i.d.; 2.5µm particle size; Phenomenex, Torrance, CA) using a 
mobile phase gradient consisting of acetonitrile containing 0.1% formic acid and water containing 
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fitted with electrospray ionization was performed for analyte quantification. The total run time was 5 
min. The lower limit of quantification (LLOQ) for TFV and FTC was 0.586 and 2.93 ng/mL, 
respectively. The inter- and intra-day precision and accuracy for the assay was ± 10% and ± 2%, 
respectively.
Peripheral Blood Mononuclear Cells. Tenofovir diphosphate (TFV-DP) and FTC 
triphosphate (FTC-TP) were quantified at the Colorado Antiviral Pharmacology Laboratory (de-
identified) University of Colorado, using validated and routinely performed LC-MS/MS assays (11). 
The lower limit of quantification (LLOQ) for TFV-DP and FTC-TP was 5 to 10 or 100 fmol/sample, 
respectively.
Urine. TFV and FTC were quantified simultaneously in urine by the LC-MS/MS assay method 
analogous to the method for plasma (10). Urine samples were diluted 100-fold prior to analysis. The 
LLOQ for TFV and FTC were the same as mentioned above. The inter- and intra-day precision and 
accuracy for the assay was ± 18% and ± 2%, respectively.
Pharmacokinetic 
For the primary endpoint, area under the plasma concentration-time curve from zero to 72 
hours (AUC0-72h,plasma) for the T and C arm were estimated using nonparametric superposition (C arm 
only) and conventional non-compartmental analysis (NCA) (T and C arm) performed by Phoenix® 
WinNonlin® (version 6.4; Certara, Princeton, NJ). For the single-dose drug administration in the T 
+PRO treatment, AUC0-72h,plasma was calculated using the observed 0-72h plasma concentration data 
and estimated using NCA analysis only. For the multiple-dose drug administration in the C IPERGAY 
treatment, AUC0-72h,plasma was estimated as the sum of the AUC0-24h for the 1st dose from the observed 
plasma concentration data using NCA in addition to the predicted AUC24-48h and AUC48-72h for the 2nd 
and 3rd doses obtained via nonparametric superposition and NCA (Figure 3). The predicted TFV and 
FTC plasma trough concentrations (24, 48, 72h) from nonparametric superposition were compared 
to observed to assess for accuracy. The predicted concentrations were on average ±15% of 
observed concentrations. The area under the PBMC concentration-time curve from zero to 72 hours 
(AUC0-72h,PBMC) for the T +PRO and C IPERGAY treatments were calculated using the observed 
PBMC concentration data and estimated using NCA analysis (T and C treatments) performed by 
Phoenix® WinNonlin®. All AUC estimates were determined using the trapezoidal rule with linear-
up/log-down interpolation. 
Single-dose DDI pharmacokinetic parameters were also explored and estimated using 
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mg TFV/400mg FTC) using conventional NCA performed by Phoenix® WinNonlin®. Pharmacokinetic 
outcomes included elimination rate constant (kel), maximum plasma concentration (Cmax), time of 
maximum plasma concentration (tmax), single-dose area under the plasma concentration-time curve 
from zero extrapolated to infinity (AUC0-∞,SD), single-dose area under the plasma concentration curve 
from time zero to 24 hours (AUC0-24h,SD), apparent volume of distribution (Vz/F), and apparent oral 
clearance (CL/F). Since TFV and FTC observe biphasic elimination kinetics in the dataset, the 
terminal half-life (t1/2) was calculated as t1/2=0.693/kel using the 0-24 hours (alpha) and 0-72 hours 
from the T+ PRO treatment only (beta). Urinary excretion was calculated using Phoenix® 
WinNonlin®.  Urine concentrations were multiplied by total urine volume collected during the interval 
and summed, Ae0-24h to calculate amount excreted in the urine (Ae). The percentage of the dose in 
urine was calculated by: % dose in urine = Ae(mg)/272mg for TFV or Ae(mg)/400mg for FTC. Renal 
clearance was calculated by: Clrenal = Ae/AUC0-24h,SD. 
Pharmacokinetic outcomes are reported as geometric mean (GM), geometric mean ratio 
(GMR), and 90% confidence interval (90% CI). Data visualization (concentration-time profiles) is 
performed using GraphPad Prism v8.2.0 (San Diego, CA).
Statistical
Prior to performing the study, power and sample size were determined using intra-subject 
variability estimates from a previous study of daily TDF/FTC in healthy volunteers (12). To 
demonstrate bioequivalence, a total of 14 subjects with complete data were projected to provide 90% 
power to detect a mean difference of no more than 25% in the primary endpoint assuming a type I 
error rate of 0.05 and intra-subject variability as previously published (12). If the 90% CI of the AUC0-
72h,plasma and AUC0-72h,PBMC GMR were contained entirely within the pre-defined boundaries of 0.8-
1.25, then the probenecid “boosting” strategy would be considered pharmacokinetically bioequivalent 
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Results
Participant Demographics
The enrolled healthy male volunteers (n=15) were self-identified Caucasian (n=10), Asian 
(n=2), Black (n=2), and biracial (n=1). The median age of participants was 26 years (range: 18-47 
years) with a median height of 69 inches (range: 64-74) and weight of 75 kg (range: 59-86). All 
participants had a baseline CrCl >90mL/min with a median SCr of 1 mg/dL (range: 0.72-1.23 mg/dL). 
Plasma and Urine Pharmacokinetics of TFV and FTC
The plasma concentration-time profiles of the two dosing regimens (T +PRO (2 g) treatment 
vs C IPERGAY treatment) in 14 healthy volunteers are shown in Figure 1. The concentration-time 
profiles up to 24 hours capture the overall kinetics of the loading dose in the presence and absence 
of PRO for both dosing regimens. The last two time points at 48 and 72 hours are to be interpreted 
differently for the two dosing regimens. For the T +PRO treatment, the 48 and 72 hour time points 
represent a continuation of the elimination phase (1-dose regimen). For the C IPERGAY treatment, 
the 48 and 72 hour time points represent the trough concentrations, Ctr, for the 2nd and 3rd doses (3-
dose regimen). The PK effects from a single dose of PRO given with single doses of TFV (272mg) 
and FTC (400 mg) was also estimated and derived using the sampling time of 24 hours (Table 1). 
When a single dose of TDF and FTC was co-administered with 2g PRO, overall exposure (AUC0-∞,SD) 
of TFV and FTC increased by approximately 60-70% in the plasma. TFV and FTC apparent oral 
clearance, CL/F, significantly decreased by nearly 40% in the presence of PRO. A similar trend was 
observed for the apparent volume of distribution, Vz/F, of both TFV and FTC. Renal clearances of 
single dose TFV and FTC were significantly decreased in the presence of PRO. There was no 
difference in the estimated t1/2 of TFV and FTC between treatments from the single dose data. 
However, the literature suggests TFV and FTC demonstrate biphasic elimination and are long half-
life drugs (t1/2 ~ 18 h for TFV; t1/2 ~ 10h for FTC) (13). Thus, the terminal elimination t1/2 of TFV and 
FTC could not be accurately estimated from the short sampling time of 0-24 h and suggests the 
single-dose data up to 24 hours appears to primarily capture the distribution phase only of TFV and 
FTC. Since the T +PRO treatment is comprised of a single dose regimen, the concentration-time 
data over 72 hours in the T +PRO treatment was used to estimate the true terminal t1/2 with the DDI 
(+PRO). Since the C IPERGAY treatment has additional dosing at 24 and 48 hours, the true terminal 
t1/2 could not be measured from our data. Instead the terminal t1/2 from the T +PRO treatment (Table 
1) was compared to the literature and corresponds well (t1/2 ~ 18 h for TFV; t1/2 ~ 10h for FTC) (13) 
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change maximum plasma concentration (Cmax) or time to reach maximum plasma concentration 
(Tmax) of TFV. There was a 20% increase in FTC Cmax for the T +PRO treatment.
Intracellular Exposure of TFV-DP and FTC-TP
The intracellular concentration-time profiles and outcomes of TFV-DP and FTC-TP between 
the T +PRO and C IPERGAY treatments are shown in Figure 2 and Table 2. At 24 hours, TFV-DP 
and FTC-TP concentrations in the T +PRO treatment were on average 30% and 10% higher than the 
C IPERGAY treatment, respectively. The two additional doses of TDF in the C IPERGAY treatment 
resulted in nonlinear accumulation of TFV-DP. In the C IPERGAY treatment, TFV-DP intracellular 
concentrations doubled after the second dose (C48h). FTC-TP concentrations did not appear to 
increase with the additional doses and demonstrated wide variability suggesting accumulation of 
FTC-TP is unlikely. In the T +PRO treatment, TFV-DP concentrations remained consistent over the 
72 hours following single-dose administration, but FTC-TP concentrations steadily decreased over 
72 hours. At both 48 hours and 72 hours, TFV-DP and FTC-TP concentrations were significantly 
higher in the C IPERGAY treatment compared to T +PRO treatment. 
Bioequivalence Test for the Primary and Exploratory Endpoint
The AUC0-72h,plasma AUC0-72h,PBMC ratio of the T +PRO treatment compared to C IPERGAY 
treatment for TFV and FTC are shown in Table 3. Since the C IPERGAY treatment was a 3-dose 
regimen and observed PK data well-characterized the loading dose only (1st dose) along with trough 
concentrations for the 2nd and 3rd dose, the plasma AUC0-72h in the C IPERGAY treatment was 
estimated using a combination of both nonparametric superposition for the 2nd and 3rd dose and NCA 
for overall exposure of the 3 doses to accommodate for the multiple-dose regimen (see Methods). 
The observed and predicted concentration-time profiles used for calculation are shown as Figure 3. 
The primary endpoint, AUC0-72h,plasma GMR, of 0.86 was 14% (90% CI = 2-24%) lower in the T +PRO 
treatment for both TFV and FTC. T +PRO treatment did not achieve equivalent AUC0-72h,plasma 
exposure compared to C IPERGAY HIV PrEP. The PBMC AUC0-72h GMR of the T +PRO treatment 
compared to C IPERGAY treatment was 23% and 29% lower in the T +PRO treatment for TFV-DP 
and FTC-TP, respectively (Table 3). Therefore, the overall intracellular exposures of TFV-DP and 
FTC-TP of the T + PRO treatment were not equivalent to the C IPERGAY treatment. 
The single-dose plasma AUC0-∞,SD was also compared to further assess the drug-drug 
interaction potential of PRO with TDF and FTC (Table 3). The comparison of the AUC0-∞,SD showed 
that the T +PRO boosted the overall single-dose exposure by 60-70% (TFV GMR = 1.61, 90% CI = 
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Safety 
All healthy volunteers enrolled were included in the safety analysis. The observed AEs are 
summarized in Table S1. Overall, the reported AEs were considered low grade in severity (grade 1 
and 2). Eighteen adverse events occurred during the entire study with 8 of the 15 subjects enrolled 
experiencing at least one adverse event. Subjects in the T +PRO treatment experienced more 
adverse events than the C IPERGAY treatment. The most common adverse event was nausea 
followed by headache. One subject withdrew from the study due to gastroesophageal reflux disease 
(GERD) which occurred 2 weeks after T +PRO treatment was completed during the washout period 
and required medical intervention. This incident was determined probable (and not definitely) related 
to the study intervention since it occurred during the washout period. Of note, the subject reported 
prior history of gastric reflux.
In the T +PRO treatment, serum creatinine significantly increased from baseline at 24 and 72 
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Discussion
This work is the first to report 1) the clinical pharmacokinetic outcomes of TDF/FTC in the 
presence of PRO and 2) the multiple-dose plasma TFV/FTC and intracellular TFV-DP/FTC-TP 
disposition profiles for the IPERGAY HIV PrEP regimen. 
In the present study, when a single dose of TDF and FTC was given with PRO, PRO 
increased TFV and FTC plasma exposure to similar extent (by approximately 60-70%) and 
decreased total and renal clearances. A decrease in the volume of distribution, V/F, for TFV and FTC 
was also observed. It should be noted that we have used NCA for estimation of V/F, which inherently 
limits mechanistic interpretation for orally administered agents. However, inhibition of OAT1/3 by 
PRO leads to decreased TFV uptake into renal cells available for elimination and thus increases TFV 
in circulation and may lower V/F because more of the drug is in the blood and less is escaping into 
renal cells for removal. At 24 hours after dosing, a modest but statistically significant increase in 
intracellular TFV-DP concentrations (~30%; p=0.024) were noted while FTC-TP concentrations were 
not different between T +PRO and C IPERGAY treatments. TFV and FTC are predominantly cleared 
by the kidney via glomerular filtration and active secretion. The glomerular filtration of these drugs is 
not affected by PRO because the renal clearances exceed the GFR (>90 mL/min) in the presence of 
PRO. It is well established that OAT-mediated (OAT1 and OAT3) active uptake in to the proximal 
tubule as well as MRP-mediated (MRP4) efflux to the tubular lumen are responsible for the renal 
secretion of TFV (8). In vitro studies indicate that PRO inhibits OAT1 and OAT3 at therapeutically 
relevant concentrations. Indeed, PRO is known to alter the pharmacokinetics of several OAT1/OAT3 
substrates.  Although PRO-mediated clinical drug interactions with “substrates” of MRP4 have been 
reported, there is no clear evidence in vitro that PRO is an inhibitor of MRP4 (14, 15). We noted that 
PRO also increased serum creatinine, a known substrate of OAT1 and OAT3. It follows that the 
mechanism by which PRO increased TFV plasma exposure in the present study could be attributed 
to inhibition of OAT1/OAT3 by PRO. Of note, the effect of PRO on TFV exposure was relatively small 
(~60% increase) compared to its effects on other substrates of OAT1 and OAT3 such as cefoxitin 
and furosemide, which were over 2-fold (16, 17). This could be in part due to differences in the 
contribution of active tubular secretion to the total renal excretion or in differences in systemic 
metabolism which may be affected by PRO. PRO is known reduce clearance of many drugs via 
inhibition of OAT1 and OAT3 substrates in various drug classes including antivirals (i.e. oseltamivir, 
ganciclovir, acyclovir), antibacterials (i.e. nafcillin, ciprofloxacin) and antihistamines (i.e. ranitidine, 
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should be taken in to account when evaluating risk/benefit of PRO addition.  The contribution of 
tubular secretion (20-30%) to the overall excretion of TFV renal excretion is relatively small. In 
contrast to TFV, the specific renal transporters involved in FTC secretion have not been 
unequivocally identified. Based on in vitro data, FTC renal secretion is generally believed to be 
mediated through OCT transporters on the basolateral membrane (8, 19). In this context, the 
significant increase in FTC exposure by PRO observed in the present study was unexpected. OAT3 
was also implicated in the uptake transport of FTC in vitro, although the primary data were not 
available to evaluate this claim (19). The specific rate-limiting active transporter responsible for FTC 
renal secretion remains to be established. Although PRO is generally believed to be selective 
inhibitor of OATs, the possibility that it may also inhibit OCTs cannot be ruled out. Additional studies 
are needed to confirm the specific mechanisms underlying this observed drug-drug interaction. 
Intracellular concentrations of TFV-DP and FTC-TP from single dose 600 mg TDF / 400 mg 
FTC at 24h were similar to published observations (20). After single dose TDF and PRO, TFV-DP 
concentration remains unchanged over 72 hours demonstrating a long intracellular half-life. After 
multiple doses, our data shows TFV-DP demonstrates a non-linear accumulation in PBMC. It is 
reported that TFV-DP has a t1/2 of 2 days after a single dose and 4-7 days at steady state in PBMC 
(20-24). Our data suggests that when TFV is given with PRO, TFV-DP t1/2 is longer than 3 days. In 
contrast, after single dose FTC and PRO, there is a decline in FTC-TP concentration between 24h 
and 72h in a linear and first-order fashion suggesting our sampling times captured the elimination 
phase of FTC. This would be supported by the literature suggesting FTC-TP t1/2 is 17-33 hours (23, 
24). It is reported that FTC-TP achieves maximum concentrations within 2-4 hours. Thus, PBMC 
sampling at an earlier time (i.e. 2-4 h after dose) may better capture maximum FTC-TP 
concentrations (23). For TFV-DP, the reported median time to achieve Cmax is 12 hours (IQR: 8-96h) 
(23) suggesting we may have caught some, but not all individuals Cmax for TFV-DP at the 24 hours 
sample collection (GM 15 fmol/106 cells for C treatment; 20 fmol/106 for T treatment) as well. This is 
a limitation for analysis if Cmax of active metabolites is a pertinent parameter for antiretroviral activity. 
FTC-TP intracellular accumulation is unclear after multiple doses, with a mild increase at 48h and 
decrease at 72h. FTC-TP was reported to have a 1.7-fold accumulation in PBMC from single dose to 
steady state (~3 days) (22). It is difficult to draw conclusions for FTC-TP concentrations in the control 
arm due to differences in sampling time. 
The overall probenecid-boosted TFV and FTC AUC0-72h,plasma and AUC0-72h,PBMC did not meet 
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4 to 12 hours half-life of probenecid (25), it is not surprising that the effects of probenecid on TFV 
and FTC would be much less evident during the 2nd or 3rd days of the study. An important limitation of 
our study is that estimation of the true elimination phase in the C IPERGAY treatment was not 
accurately captured due to the study design. Since nonparametric superposition is based on the 
accumulation ratio computed from the terminal phase slope, kel, and this is a cross-over study, we 
used each participant’s kel from the T +PRO treatment for nonparametric superposition of the 2nd and 
3rd dose in the C IPERGAY treatment to estimate AUC0-72h,plasma under the assumption that the kel for 
each individual in the T +PRO treatment was not effected by PRO. This is supported by the terminal 
t1/2 from the T +PRO treatment corresponding well with literature data (18) for TFV (~ 18 h) and FTC 
(~ 10 h) without PRO, suggesting PRO did not impact the overall t1/2 and provided justification for the 
method. Therefore, we believe that this estimation is reasonable for the primary endpoint. 
The required concentrations of TFV-DP and FTC-TP in PBMCs for On-demand PrEP to 
prevent HIV infection is not well established, making it difficult to predict the clinical relevance of 
single-dose PRO-boosted TDF. Anderson et al. established previously TFV-DP concentrations 
above 16 fmol/106 cells (95% CI: 3-28) and FTC-TP above 3.7 (95% CI: 1.2-6.1) pmol/106 cells in 
PBMCs were associated with a 90% reduction in the risk of acquiring HIV-1 infection for daily 
TDF/FTC HIV PrEP (26). However, these intracellular efficacy “cut-off” concentrations are difficult to 
confidently apply outside of this study by Anderson et al. due to unknown drug degradation 
parameters from prolonged storage of their PBMC samples whereas in our study PBMC intracellular 
concentrations were measured relatively quickly. Rectal mucosal tissue is one of the first sites 
susceptible for HIV transmission in MSM and TGW. Active drug exposure at initial sites vulnerable 
for HIV acquisition is crucial for non-daily HIV PrEP (27). Literature suggests the TFV-DP rectal 
mononuclear cell to intracellular (PBMC) concentrations are more than 10 times greater and reach 
steady state within 5 days (23, 27), while FTC-TP rectal concentrations are negligible but highest in 
PBMC cells reaching maximum concentrations within 2-4 hours (20, 23). Due to financial and 
practical considerations, rectal biopsies were not obtained in this study but would undoubtedly 
contribute to interpretation of HIV PrEP pharmacokinetic analysis. This may suggest TDF is the 
moiety in TDF/FTC that provides prolonged rectal HIV protection while FTC may provide rapid PBMC 
protection in non-daily HIV PrEP regimens. In this context, the clinical relevance of our findings 
require further investigation; until then we strongly recommend that the PRO regimen not be 










This article is protected by copyright. All rights reserved
Although the PRO regimen was tolerated, there were more frequent episodes of adverse 
events, in particular nausea, with the T PRO arm. This may have practical implications as a PrEP 
agent would have to be extremely well-tolerated to allow sufficient adherence to be clinically 
effective. Of note, PRO given with zidovudine has previously been shown to lead to adverse 
systemic cutaneous reactions in HIV-positive patients (28). Thus, if a probenecid based PrEP 
regimen failed, there would be a risk of similar severe reactions developing in the newly infected 
person. Thus, a probenecid based regimen would have to be proven well-tolerated in large trials 
before it could be practically employed. 
In summary, we have shown for the first time that PRO reduces the renal secretion of TFV via 
inhibition of OAT1 and OAT3. We also observed that PRO increased plasma exposure of FTC. This 
interaction was unexpected and mechanistic studies are warranted. As nondaily HIV PrEP with 
TDF/FTC becomes more widely accepted, therapy optimized for patient adherence, reduce pill 
burden, and cost may provide the foundation for HIV PrEP worldwide, particularly in countries with 
resource- and healthcare- limited settings. Our findings provide proof-of-concept that inhibition of 
renal transporters alter the disposition of TFV/FTC. However, whether these data would be adequate 
to recommend PRO-boosted TFV/FTC regimen as simplified and cost-effective PrEP needs further 
study, particularly to confirm the required intracellular concentrations of these agents for On-demand 
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Study Highlights
What is the current knowledge on the topic?
A combination pill containing 300 mg TDF / 200 mg FTC is highly efficacious in preventing 
new HIV infections when given daily or as multiple-dose ‘on demand’ drug administration. Tenofovir 
(TFV), major metabolite of TDF found in circulation, undergoes renal secretion via OAT 1 and 3. 
Probenecid is a known inhibitor of OAT 1 and 3.
What question did this study address?
We hypothesize that inhibition of OAT 1 and OAT 3 by probenecid will increase TFV plasma 
exposure and the intracellular concentrations of its active metabolite (TFV-diphosphate), providing 
clinical benefit to allow a less expensive, single-dose HIV prevention regimen of TDF/FTC.
What does this study add to our knowledge?
Probenecid boosted plasma exposure of TFV and initial intracellular exposure of its active 
metabolite. Probenecid also increased plasma FTC exposure. However, formal bioequivalence was 
not achieved.
How might this change clinical pharmacology or translational science?   
While the interaction of TFV with probenecid was expected, an unexpected interaction 
between probenecid and FTC was identified. Additional investigation will need to determine the 
clinical utility of probenecid-boosted TDF/FTC for HIV prevention.
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Figure Legends
Figure 1. GM and 95% CI for plasma concentration-time profiles for TFV (top) and FTC (bottom) 
concentrations for the T +PRO (open blue squares) and C IPERGAY (closed black circles) 
treatments.
Figure 2. GM and 95% CI intracellular concentration-time profiles of TFV-DP (top) and FTC-TP 
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Figure 3. Individual concentration-time profiles for multiple-doses of TDF and FTC in C IPERGAY 
treatment with predicted additional doses (grey lines) overlay observed data for TFV (black solid 
circles) and FTC (blue open squares).
Figure 4. Study Design. Study periods are shown in days 1-4. Study interventions are (1) “T” test 
+PRO Treatment = 2 g PRO + 600 mg TDF/ 400 mg FTC at t=0 h or (2) “C” control IPERGAY 
Treatment = 600 mg TDF/ 400 mg FTC at t=0 h; 300 mg TDF/ 200 mg FTC at t= 24, 48 h. Treatment 
regimens were separated by ≥ 6 weeks wash-out period.
Tables
Table 1. Single-dose pharmacokinetics of TFV and FTC in the test (T +PRO) and control (C -PRO) 
treatments represented as geometric mean (GM) or geometric mean ratio (GMR, T/C) and 90% 
confidence intervals (90% CI). * represents median values; a is recovered up to 24 hour data; b 72 is 
recovered up to 24 hour data.
Table 2. Geometric mean (GM) intracellular TFV-DP and FTC-TP concentrations in the T +PRO and 
Control IPERGAY treatments and geometric mean ratio (GMR, T/C) and 90% confidence intervals 
(90% CI).
Table 3. Geometric least square mean AUC equivalence test for TFV/TFV-DP and FTC/FTC-TP in 
the test (T, +PRO) compared to control (C, IPERGAY) treatments and GMR (T/C) with 90% 
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Table 1. 
PK Parameters 
Tenofovir (TFV) Emtricitabine (FTC) 
 C T GMR (T/C) C T GMR (T/C) 
C
max
 (ng/mL) 529 538 1 3426 4108 1.2 
 (464-602)  (502-577) (0.91-1.1) (3137-4806) (3720-4535) (1.0-1.4) 
T
max




 (1-4) (1-2)  (1-4) (1-4)  
AUC
0-INF,SD
 (ng*h/mL) 3958 6444 1.6 20635 34030 1.7 
 (3618-4331) (5827-7127) (1.5-1.8) (18984-22431) (30886-37494) (1.5-1.9) 
AUC0-24h,SD (ng*h/mL)  3026  4963  1.6  19488  31482  1.6  
 (2799-3271)  (4576-5385) (1.5-1.8)  (17830-21300)  (28856-34346)  (1.4-1.8)  
CL/F (L/h) 69 43 0.61 19 12 0.61 
 (50-95) (29-63) (0.56-0.67) (18-21) (11-13) (0.54-0.69) 
k
el






















  18   10  
  (16-19)   (8-12)  
Vz/F (L) 1278 676 0.57 192 119 0.62 
 (886-1841) (495-923) (0.51-0.64) (158-231) (107-132) (0.53-0.73) 
% dose in urine
c
  17 17  62 68  
 (14-21) (15-21)  (53-72) (57-80)  
Clrenal
c
 (mL/min) 257 158 0.60 210 153 0.7 
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Table 1. Single-dose pharmacokinetics of TFV and FTC in the test (T +PRO) and control (C -PRO) treatments represented as 
geometric mean (GM) or geometric mean ratio (GMR, T/C) and 90% confidence intervals (90% CI). Plasma pharmacokinetic 
parameters are recovered up to 24 hour data; * represents median values; a is recovered up to 24 hour data; b is recovered up to 72 















 C T GMR (T/C)  C  T GMR (T/C) 
C
24h
 (fmol/106 cells) 15 20 1.3 1861 2077 1.1 
 
(13-19) (17-23) (1.0-1.6) (1523-2274) (1716-2512) (0.88-1.4) 
C
48h
 (fmol/106 cells) 32 23 0.7 2029 1103 0.54 
 





cells) 34 21 0.6 1671 639 0.38 
 
(29-41) (16-26) (0.42-0.86) (1318-2118) (488-838) (0.26-0.56) 
 
Table 2. Geometric mean (GM) intracellular TFV-DP and FTC-TP concentrations in the T +PRO and Control IPERGAY treatments 
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Table 3. 
 




























19.6 32.8 1.68 (1.48-1.89) 
 
Table 3. Geometric least square mean AUC equivalence test for TFV (plasma),TFV-DP (PBMC) 
FTC (plasma), and FTC-TP (PBMC) in the test (T, +PRO) compared to control (C, IPERGAY) 
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